Ferronova

Executive Summary

Ferronova is an Australian med-tech company developing FerroTrace®, a novel mannose-labelled super-paramagnetic iron-oxide nanoparticle tracer for intra-operative and pre-operative lymph node mapping in upper gastrointestinal cancers. The technology combines MRI, a handheld magnetometer, and near-infrared imaging to improve staging accuracy, surgical planning, and radiotherapy targeting. Founded in 2016 and currently in Phase 1 clinical development, Ferronova addresses a significant unmet need in high-risk lymph node assessment, where current techniques often miss metastatic nodes. The company is private and has not disclosed total funding, but its technology offers a potential to reduce unnecessary lymphadenectomies and improve patient outcomes. With a focused pipeline and a clear value proposition in oncology surgery, Ferronova is positioned for upcoming clinical and regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical trial results70% success
• TBDFDA or TGA approval for IDE or clinical trial application60% success
• TBDStrategic partnership or licensing deal for distribution40% success